SCIENCE
The Challenge
mRNA therapies are limited by delivery
Targeted RNA delivery beyond the liver remains one of the most critical and unresolved challenges in nucleic acid therapeutics. Despite decades of research and significant investment in new delivery technologies, no scalable, clinically validated solution has emerged for reaching extrahepatic tissues and specific cell types. Current LNPs are inherently liver -biased, which severely limits the therapeutic reach and impact of RNA -based medicines.
Our Solution
MOTE’s proprietary mobilize delivery platform combines hepatic detargeting with precision ligand engineering to enable delivery to extrahepatic cells and tissues
Designed for scalability and modularity, the platform allows rapid ligand -payload reconfiguration, solving key challenges in specificity, durability, and manufacturing while supporting RNA therapeutics development for multiple diseases.
RNA Targeted Delivery
The Next Frontier
